Article Text

Download PDFPDF
Efficacy of infliximab in the treatment of Erdheim-Chester disease

Statistics from Altmetric.com

Footnotes

  • Handling editor Josef S Smolen

  • Contributors FC-A, ZA and JH designed the study. FC-A, J-FE, NB, FC, PM and JH collected the data. J-FE and FC centrally reviewed the histological samples. J-FE determined the BRAF status. FC-A and JH conducted the statistical analysis. FC-A, J-FE, FC, ZA, PM, PC and JH analysed and interpreted the data. PM centrally reviewed the PET-CT scans. FC-A, J-FE, ZA and JH wrote the manuscript. All authors critically reviewed and approved the final version of the manuscript.

  • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Ethics approval CPP Ile de France III.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.